No headlines found.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Globe Newswire (Thu, 18-Apr 8:45 AM ET)
Globe Newswire (Mon, 15-Apr 8:55 AM ET)
Globe Newswire (Wed, 10-Apr 8:21 AM ET)
Globe Newswire (Tue, 2-Apr 7:30 AM ET)
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Globe Newswire (Thu, 28-Mar 8:05 AM ET)
Globe Newswire (Tue, 26-Mar 9:05 AM ET)
Globe Newswire (Mon, 25-Mar 9:05 AM ET)
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
Globe Newswire (Fri, 15-Mar 8:45 AM ET)
AIM ImmunoTech Announces Launch of CEO Corner Platform
Globe Newswire (Thu, 7-Mar 8:45 AM ET)
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Aim Immunotech trades on the AMEX stock market under the symbol AIM.
As of April 24, 2024, AIM stock price climbed to $0.43 with 157,335 million shares trading.
AIM has a beta of 1.53, meaning it tends to be more sensitive to market movements. AIM has a correlation of 0.05 to the broad based SPY ETF.
AIM has a market cap of $21.82 million. This is considered a Sub-Micro Cap stock.
Last quarter Aim Immunotech reported $65,000 in Revenue and -$.26 earnings per share. This beat revenue expectation by $25,000 and missed earnings estimates by -$.11.
In the last 3 years, AIM stock traded as high as $2.40 and as low as $.29.
The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF.
AIM has underperformed the market in the last year with a price return of -15.4% while the SPY ETF gained +24.2%. AIM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning 0.0% and -13.0%, respectively, while the SPY returned +4.6% and -2.7%, respectively.
AIM support price is $.39 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM stock will trade within this expected range on the day.